Presbia Surpasses Treatment of 300 Subjects as Part of the US FDA Pivotal Study Enrollment

DUBLIN--(BUSINESS WIRE)--Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near vision restoration announced today that it is approaching completion of patient enrollment of its U.S. Food and Drug Administration (FDA) pivotal study for the Presbia Flexivue MicrolensTM. Presbia has a proprietary optical lens implant for treating presbyopia, the gradual loss of near vision. The company will submit its Final PMA module to the FDA for approval of the Flexivue Microlens after 30

Full Story →